Key terms
About STIM
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest STIM news
Mar 28
4:27pm ET
Neuronetics Inc Shrinks Board Following Strategy Review
Mar 26
7:16am ET
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
Mar 25
8:51am ET
NeuroStar Advanced Therapy receives FDA clearance
Mar 07
8:23am ET
Neuronetics announces 5-year exclusive partnership with TCN
Mar 06
4:14pm ET
Neuronetics Inc Boosts Executive Compensation for Top Leaders
Mar 06
7:37am ET
Piper Sandler Sticks to Their Buy Rating for Neuronetics (STIM)
Mar 06
7:22am ET
Neuronetics price target raised to $8 from $7 at Piper Sandler
Mar 06
12:30am ET
Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Marinus (MRNS) and Gritstone Oncology (GRTS)
Mar 05
7:42am ET
Neuronetics Inc Shares New Investor Insights Online
Mar 05
7:41am ET
Neuronetics reports Q4 EPS (19c), consensus (26c)
Feb 12
8:34am ET
Neuronetics announces enhancements to TrakStar Patient Data Management System
Feb 06
8:29am ET
Neuronetics TMS patient access expands through Lucet Health policy update
Jan 09
7:53am ET
Neuronetics Stock Receives Buy Rating from Canaccord Genuity Amid Strong Q4 Performance and Positive Outlook
Jan 08
8:48am ET
Neuronetics sees 2023 revenue over $71M, consensus $70.77M.
Jan 08
8:47am ET
Neuronetics sees Q4 revenue over $20M, consensus $19.76M
No recent press releases are available for STIM
STIM Financials
Key terms
Ad Feedback
STIM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
STIM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range